vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and Forestar Group Inc. (FOR). Click either name above to swap in a different company.
Forestar Group Inc. is the larger business by last-quarter revenue ($273.0M vs $183.1M, roughly 1.5× Amphastar Pharmaceuticals, Inc.). Amphastar Pharmaceuticals, Inc. runs the higher net margin — 13.3% vs 5.6%, a 7.7% gap on every dollar of revenue. On growth, Forestar Group Inc. posted the faster year-over-year revenue change (9.0% vs -1.8%). Amphastar Pharmaceuticals, Inc. produced more free cash flow last quarter ($24.6M vs $-157.1M). Over the past eight quarters, Amphastar Pharmaceuticals, Inc.'s revenue compounded faster (3.2% CAGR vs -9.6%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
Forestar Group Inc. is a residential lot development company based in Arlington, Texas. The company has operations in 51 markets in 21 states and delivered 11,518 residential lots during the twelve-month period ended December 31, 2020. The company is publicly traded on the New York Stock Exchange and in October 2017 became a majority-owned subsidiary of D.R. Horton, Inc., the largest homebuilder by volume in the United States since 2002. The company primarily acquires entitled real estate and...
AMPH vs FOR — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $273.0M |
| Net Profit | $24.4M | $15.4M |
| Gross Margin | 46.8% | 20.1% |
| Operating Margin | 19.4% | 7.6% |
| Net Margin | 13.3% | 5.6% |
| Revenue YoY | -1.8% | 9.0% |
| Net Profit YoY | -35.7% | -6.7% |
| EPS (diluted) | $0.51 | $0.30 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | $273.0M | ||
| Q3 25 | $191.8M | $670.5M | ||
| Q2 25 | $174.4M | $390.5M | ||
| Q1 25 | $170.5M | $351.0M | ||
| Q4 24 | $186.5M | $250.4M | ||
| Q3 24 | $191.2M | $551.3M | ||
| Q2 24 | $182.4M | $318.4M | ||
| Q1 24 | $171.8M | $333.8M |
| Q4 25 | $24.4M | $15.4M | ||
| Q3 25 | $17.4M | $86.9M | ||
| Q2 25 | $31.0M | $32.9M | ||
| Q1 25 | $25.3M | $31.6M | ||
| Q4 24 | $38.0M | $16.5M | ||
| Q3 24 | $40.4M | $81.5M | ||
| Q2 24 | $37.9M | $38.7M | ||
| Q1 24 | $43.2M | $45.0M |
| Q4 25 | 46.8% | 20.1% | ||
| Q3 25 | 51.4% | 22.3% | ||
| Q2 25 | 49.6% | 20.4% | ||
| Q1 25 | 50.0% | 22.6% | ||
| Q4 24 | 46.5% | 22.0% | ||
| Q3 24 | 53.3% | 23.9% | ||
| Q2 24 | 52.2% | 22.5% | ||
| Q1 24 | 52.4% | 24.9% |
| Q4 25 | 19.4% | 7.6% | ||
| Q3 25 | 13.2% | 16.9% | ||
| Q2 25 | 24.2% | 11.2% | ||
| Q1 25 | 21.9% | 11.6% | ||
| Q4 24 | 24.2% | 8.7% | ||
| Q3 24 | 29.8% | 19.7% | ||
| Q2 24 | 30.3% | 16.2% | ||
| Q1 24 | 27.9% | 17.6% |
| Q4 25 | 13.3% | 5.6% | ||
| Q3 25 | 9.0% | 13.0% | ||
| Q2 25 | 17.8% | 8.4% | ||
| Q1 25 | 14.8% | 9.0% | ||
| Q4 24 | 20.4% | 6.6% | ||
| Q3 24 | 21.1% | 14.8% | ||
| Q2 24 | 20.8% | 12.2% | ||
| Q1 24 | 25.1% | 13.5% |
| Q4 25 | $0.51 | $0.30 | ||
| Q3 25 | $0.37 | $1.70 | ||
| Q2 25 | $0.64 | $0.65 | ||
| Q1 25 | $0.51 | $0.62 | ||
| Q4 24 | $0.74 | $0.32 | ||
| Q3 24 | $0.78 | $1.59 | ||
| Q2 24 | $0.73 | $0.76 | ||
| Q1 24 | $0.81 | $0.89 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $211.7M |
| Total DebtLower is stronger | $608.7M | $793.2M |
| Stockholders' EquityBook value | $788.8M | $1.8B |
| Total Assets | $1.6B | $3.2B |
| Debt / EquityLower = less leverage | 0.77× | 0.44× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | $211.7M | ||
| Q3 25 | $276.2M | $379.2M | ||
| Q2 25 | $231.8M | $189.2M | ||
| Q1 25 | $236.9M | $174.3M | ||
| Q4 24 | $221.6M | $132.0M | ||
| Q3 24 | $250.5M | $481.2M | ||
| Q2 24 | $217.8M | $359.2M | ||
| Q1 24 | $289.6M | $416.2M |
| Q4 25 | $608.7M | $793.2M | ||
| Q3 25 | $608.6M | $802.7M | ||
| Q2 25 | $607.7M | $872.8M | ||
| Q1 25 | $603.9M | $872.5M | ||
| Q4 24 | $601.6M | $806.8M | ||
| Q3 24 | $596.4M | $706.4M | ||
| Q2 24 | $586.9M | $706.1M | ||
| Q1 24 | $594.0M | $705.7M |
| Q4 25 | $788.8M | $1.8B | ||
| Q3 25 | $776.7M | $1.8B | ||
| Q2 25 | $757.5M | $1.7B | ||
| Q1 25 | $751.3M | $1.6B | ||
| Q4 24 | $732.3M | $1.6B | ||
| Q3 24 | $727.7M | $1.6B | ||
| Q2 24 | $713.3M | $1.5B | ||
| Q1 24 | $672.4M | $1.5B |
| Q4 25 | $1.6B | $3.2B | ||
| Q3 25 | $1.7B | $3.1B | ||
| Q2 25 | $1.6B | $3.1B | ||
| Q1 25 | $1.6B | $3.0B | ||
| Q4 24 | $1.6B | $3.0B | ||
| Q3 24 | $1.5B | $2.8B | ||
| Q2 24 | $1.5B | $2.7B | ||
| Q1 24 | $1.6B | $2.6B |
| Q4 25 | 0.77× | 0.44× | ||
| Q3 25 | 0.78× | 0.45× | ||
| Q2 25 | 0.80× | 0.52× | ||
| Q1 25 | 0.80× | 0.53× | ||
| Q4 24 | 0.82× | 0.50× | ||
| Q3 24 | 0.82× | 0.44× | ||
| Q2 24 | 0.82× | 0.47× | ||
| Q1 24 | 0.88× | 0.48× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $-157.0M |
| Free Cash FlowOCF − Capex | $24.6M | $-157.1M |
| FCF MarginFCF / Revenue | 13.4% | -57.5% |
| Capex IntensityCapex / Revenue | 4.5% | 0.0% |
| Cash ConversionOCF / Net Profit | 1.35× | -10.19× |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | $93.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | $-157.0M | ||
| Q3 25 | $52.6M | $256.3M | ||
| Q2 25 | $35.6M | $15.8M | ||
| Q1 25 | $35.1M | $-19.8M | ||
| Q4 24 | $29.0M | $-450.0M | ||
| Q3 24 | $60.0M | $119.2M | ||
| Q2 24 | $69.1M | $-61.7M | ||
| Q1 24 | $55.3M | $-59.2M |
| Q4 25 | $24.6M | $-157.1M | ||
| Q3 25 | $47.2M | $255.6M | ||
| Q2 25 | $25.0M | $15.0M | ||
| Q1 25 | $24.4M | $-20.5M | ||
| Q4 24 | $16.6M | — | ||
| Q3 24 | $46.2M | $118.4M | ||
| Q2 24 | $63.1M | $-62.3M | ||
| Q1 24 | $46.5M | $-59.8M |
| Q4 25 | 13.4% | -57.5% | ||
| Q3 25 | 24.6% | 38.1% | ||
| Q2 25 | 14.3% | 3.8% | ||
| Q1 25 | 14.3% | -5.8% | ||
| Q4 24 | 8.9% | — | ||
| Q3 24 | 24.1% | 21.5% | ||
| Q2 24 | 34.6% | -19.6% | ||
| Q1 24 | 27.1% | -17.9% |
| Q4 25 | 4.5% | 0.0% | ||
| Q3 25 | 2.8% | 0.1% | ||
| Q2 25 | 6.1% | 0.2% | ||
| Q1 25 | 6.3% | 0.2% | ||
| Q4 24 | 6.7% | 0.0% | ||
| Q3 24 | 7.2% | 0.1% | ||
| Q2 24 | 3.3% | 0.2% | ||
| Q1 24 | 5.1% | 0.2% |
| Q4 25 | 1.35× | -10.19× | ||
| Q3 25 | 3.03× | 2.95× | ||
| Q2 25 | 1.15× | 0.48× | ||
| Q1 25 | 1.39× | -0.63× | ||
| Q4 24 | 0.76× | -27.27× | ||
| Q3 24 | 1.48× | 1.46× | ||
| Q2 24 | 1.82× | -1.59× | ||
| Q1 24 | 1.28× | -1.32× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
FOR
| D.R.Horton Inc. | $183.8M | 67% |
| Other | $89.2M | 33% |
